PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media276531ArticlesСтатьиPriority directions in migraine treatmentПРИОРИТЕТНЫЕ НАПРАВЛЕНИЯ В ЛЕЧЕНИИ МИГРЕНИTabeevaG RТабееваГ Р

ММА им. И.М. Сеченова, Москва

TabeevaG RММА им. И.М. Сеченова, Москва20032009166NO6 (2009)№6 (2009)646922022023Copyright ©; 2009, Bionika MediaCopyright ©; 2009, ООО «Бионика Медиа»2009Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/276531

Migraine is a chronic disease that breaks conventional lifestyle, performance efficiency, leading to patients disadaptation. The paper discusses the problem of therapy and prevention of migraine attacks. We considered drugs of different pharmacological groups used for the treatment of acute pain attacks and preventive therapy. It is emphasized that the prevention of migraine is one of the most effective ways to disease control. The requirement for preventive therapy is determined not only the frequency, duration and intensity of migraine attacks. The indications for preventive treatment are: high level of patients disadaptation, the presence of comorbid disorders, complications of migraine and high risk disease "chronification".

Мигрень является хроническим заболеванием, нарушающим привычный образ жизни, работоспособность, приводящим к дезадаптации пациентов. Обсуждается проблема терапии и профилактики приступов мигрени. Рассматриваются лекарственные средства различных фармакологических групп, применяемые для лечения острых болевых приступов и превентивной терапии. Подчеркивается, что профилактика мигрени является одним из самых эффективных способов борьбы с этим заболеванием. Необходимость проведения превентивной терапии определяется не только частотой, длительностью и интенсивностью мигренозных приступов. Показаниями к профилактическому лечению являются: высокий уровень дезадаптации больных, наличие коморбидных расстройств, осложнения мигрени и высокий риск хронификации заболевания.

headachemigraineanalgesicsnonsteroidal anti-inflammatory drugsspecific antimigrain drugsprevention of migraineголовная больмигреньанальгетикинестероидные противовоспалительные средстваспецифические антимигренозные средствапрофилактика мигрениLipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from American Migraine Study. Headache 1998;38:87-96.Lipton RB, Amatniek JC, Ferrari MD, et al. Migraine: Identifying and removing barriers to care. Neurology 1994;44(Suppl. 4):63-68.Ferrari A, Pasciullo G, Savino G, et al. Headache treatment before and after the consultation of a specialized center: a pharmacoepidemiologic study. Cephalalgia 2004;24:356-62.Wenzel RG, Schommer JC, Marks TG. Morbidity and medication preferences in individuals with headache presenting to a community pharmacy. Headache 2004;44:90-94.Malik SN, Hopkins M, Young WB, et al. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache 2006;46:773-80.Diamond ML, Wenzel RG, Nissan GR. Optimizing migraine therapy: evidence-based and patient-centered care. Expert Rev Neurother 2006;6:911-19.Landy S. Migraine throughout the life cycle. Treatment through the ages. Neurology 2004;62(Suppl. 2):2-8.Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42 (Suppl. 1):3-9.Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001;41:638-45.Diamond S, Bigal ME, Silberstein SD, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63.Lucas C, Chaffaut C, Artaz MA, et al. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005;25:267-79.Morillo LE, Alarson F, Aranaga N. Latin American Migraine Study Group. Clinical characteristics and patterns of medication use of migraineurs in Latin America from 12 cities in 6 countries. Headache 2005;45:118-26.Borkum JM. Elements of behavioral medicine treatment. In: Borkum JM Chronic headaches: biology, psychology, and behavioral treatment. Lawrence Erlbaum Associates 2007:321-50.Melchart D, Linde K, Fischer P. Acupuncture for idiopathic headache. Cochrane Database Syst Rev 2002;3:CD001218.van der Kuy PH, Merkus FW, Lohman JJ, et al. Hydroxycobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalagia 2002;22(7):513-19.Sandor PS, Di Clemente L, Coppola G. Efficacy of Coenzyme Q10 in migraine prophylaxis: a randomizes controlled trial. Neurology 2005;64:713-715.Hershey AD, Powers SW, Vockell ALB, et al. Coenzyme Q deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47:73-80.Magis D, Deprez C, Ambrosini A, et al. A randomizes, double-dlind placebo-controlled parallel group study of thioctic (or α-lipoic) acid, 600 mg p.o. in migraine prophylaxis. Cephalalgia 2001;21(4):2-129.Magis D, Ambrosini A, Sandor P, et al. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 2007;47:52-57.Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43:9-15.Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-99.Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? Cephalagia 2006;26:769-71.Facchinetti F, Sances G, Borella P. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991;31:298-301.Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalagia 1996;16:257-63.Tfelt-Hansen P, Olesen J. Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. Eur Neurol J 1980;19:163-65.Diamond S. Treatment of migraine with isometheptene, acetaminophen and dichlorphenazone combination: a double-blind, cross-over trial. Headache 1976;16:282-87.Peatfield RC, Petty RG, Rose FC. Double blind comparison of mefamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia 1983;3:129-34.Tfelt-Hansen P, Rolan P. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraines. In: The Headaches. Olesen J., Goadsby PJ., Ramadan NM eds. 3rd ed. Lippincott Williams & Wilkins 2005;449-57.Tfelt-Hansen P, Young WB, Silberstein SD. Antiemetic, prokinetic, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: The Headaches. Olesen J., Goadsby PJ., Ramadan NM eds. 3rd ed. Lippincott Williams & Wilkins 2005;505-13.Goadsby PJ, Gundlach AL. Localization of H-dihydroergotamine binding sites in the cat central nervous system. Ann Neurol 1991;29:91-94.Dahlo C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71.Ferrari MD, Roon KI, Lipton RB. Oral triptans - serotonin 5-HT (1B/1D) agonists - in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-75.Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997;17:73-80.Saper JR, Silberstein SD, Lake AE, et al. Double-blind trial of fluoxetine: chronic daily headache in migraine. Headache 1994;34:497-502.Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia 1997;17:81-83.Silberstein SD, Neto W, Schmitt J, et al. MIGR-001 study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-95.